[Efficacy of sublingual immunotherapy and subcutaneous immunotherapy in children with allergic rhinitis].
Objective:To evaluate the efficacy and safety of sublingual immunotherapy(SLIT) and subcutaneous immunotherapy(SCIT) in children with pediatric allergic rhinitis.Method:This study retrospectively analyzed the efficacy and safety of SLIT and SCIT in 186 children with allergic rhinitis which induced by house dust mites.Patients were randomly divided into two groups:SLIT group consisted of 104 patients,and SCIT group consisted of 82 patients.These two groups were followed up 2 years and recorded on the following indexs including total rhinitis symptoms score(TRSS),visual analogue scale(VAS),the rhinoconjunctivitis quality of life questionnaire(RQLQ),skin index(SI),serum specific IgE(slgE), eosinophil cationic protein(ECP),peripheral eosinophil(EOS) and adverse reactions.Result:After 2-year treatment,both SLIT and SCIT groups showed significant reduction ins TRSS,VAS,RQLQ,SI and ECP compared with those before treatment (P <0.05),while there were no significant differences in sIgE of two groups compared with those before treatment(P>0.05).Besides,there were no significant differences between the two groups in TRSS,VAS,RQLQ,SI,sIgE,ECP and EOS (P >0.05) before or after treatment.There were 3 patients in SLIT group and 2 patients in SCIT group who showed adverse reactions.For the incidence of adverse reactions,the figures were 3.85% and 2.44%,respectively.No severe systemic side effects were registered in these two groups.Conclusion:Both SLIT and SCIT demonstrated the improvement of symptoms and quality of life in patients with pediatric allergic rhinitis.The therapeutic efficacy is consistent with SLIT and SCIT.Both SLIT and SCIT groups indicated significantly decrease in SI and ECP,which suggest that SI and ECP may be the potential indicators in efficacy evaluation.